A5026464657- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac electrophysiology and arrhythmias
- Health Systems, Economic Evaluations, Quality of Life
- Cytokine Signaling Pathways and Interactions
- Histone Deacetylase Inhibitors Research
- Eicosanoids and Hypertension Pharmacology
- Fatty Acid Research and Health
- Rheumatoid Arthritis Research and Therapies
- Alcohol Consumption and Health Effects
- Hops Chemistry and Applications
- Medication Adherence and Compliance
- Tuberculosis Research and Epidemiology
- Pneumocystis jirovecii pneumonia detection and treatment
- Infectious Diseases and Tuberculosis
- Cancer Mechanisms and Therapy
Henan Provincial People's Hospital
2016-2025
Henan University
2020-2023
Zhengzhou University
2020-2023
Beijing Chest Hospital
2018
Capital Medical University
2018
Objectives: Warfarin is often used for ischemic stroke prevention in patients with atrial fibrillation (AF), but the factors affecting patient adherence to warfarin therapy have not been fully understood. Methods: A cross-sectional survey was conducted AF undergoing at least 6 months prior study. The clinical data collected using questionnaires by phone interviews included following: 1) self-reported measured Morisky Medication Adherence Scale-8 © ; 2) beliefs about medicines surveyed...
Background The triglyceride-lowering drug, icosapent ethyl (IPE), was granted a new indication for the reduction of atherosclerotic cardiovascular disease risk in 2019. This study aimed to investigate safety profile IPE by mining FDA Adverse Event Reporting System (FAERS) database.
Atrial fibrillation (AF) is an arrhythmia that prevalent globally, and its incidence grows exponentially with aging. Non-vitamin K antagonist oral anticoagulants (NOACs) have been developed in recent years, it challenges the supremacy of warfarin for thromboembolism prophylaxis AF. Nevertheless, there are limited data specifically evaluating real-life use NOACs elderly patients AF China.This a national, multicenter, non-interventional, cross-sectional study enrolls aged 75 years above from...
Patients with non-valvular atrial fibrillation (NVAF) exhibit a high risk of stroke, which is associated mortality. Thus, stroke prevention crucial for the overall management NVAF. Two categories drugs, vitamin K antagonist warfarin and non-vitamin oral anticoagulants (NOACs), are clinically used to prevent NVAF-related stroke. In some circumstances, NOACs superior warfarin. However, selection NVAF patients affected by many factors, including individual patient characteristics,...
Combined antithrombotic regimens for atrial fibrillation (AF) patients with coronary artery disease, particularly those who have acute syndrome (ACS) and/or are undergoing percutaneous intervention (PCI), presents a great challenge in the real-world clinical scenario. Conventionally, triple therapy (TAT), which consists of combined oral anticoagulant to prevent systemic embolism or stroke along dual antiplatelet arterial thrombosis (CAT), is used. However, TAT has been associated...
The aromatic <em>Baeckea frutescens</em> leaves (BFL) known as "Gang-Song-Cha" is a popular drink (Tea) in South China. To explore the healthcare value, systematic and in-depth study on BFL alleviating rheumatoid arthritis (RA) was carried out by integrating network pharmacology, molecular docking, experimental verification. efficacy first evaluated, extract could ameliorate RA inhibiting articular swelling, lowering immune organ index, improving ankle pathologies, regulating serum levels of...
Aim: As the non-vitamin K antagonist oral anticoagulant (NOAC) most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated prevalence of and contemporary trends prescription among Chinese patients as well factors associated with its inappropriate a multi-center registry treated real-world practice. Methods: real-world, prospective, multicenter, non-interventional included 1005 inpatients edoxaban. According National Medical Products...
As the direct oral anticoagulant most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated prevalence of and contemporary trends prescription among Chinese patients as well factors associated with its inappropriate a multicentre registry treated real-world practice.